Form 4: uniQure CEO Matthew Kapusta Sells Shares to Cover Tax Obligations

uniQure's CEO, Matthew Kapusta, sold 27,904 ordinary shares to cover tax obligations arising from the vesting of restricted share units.

Summary

• On February 26, 2024, Matthew Kapusta, CEO and Managing Director of uniQure N.V., sold 27,904 ordinary shares of the company.
• The sale was executed to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
• The shares were sold at a weighted average price of $6.35, with individual transactions ranging from $6.23 to $6.49.
• Following the transaction, Kapusta directly owns 440,839 ordinary shares of uniQure N.V.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (share sale for tax obligations). It's neutral in tone and doesn't indicate any significant positive or negative sentiment regarding the company's prospects.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation such as restricted stock units. This is a common practice and doesn't necessarily reflect a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive compensation practices, including equity grants and subsequent tax-related sales, are common across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize restricted stock units as part of their executive compensation packages, leading to similar tax obligation scenarios.
• The percentage of shares sold for tax purposes is generally consistent with industry norms for executives holding similar equity positions.

Key Dates